Cancer Genetics (CGIX), an early-stage diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to cancer treatment, lowers its IPO amount to 1.65M shares at an offering price of $10 to $12 per share. The company's previous filing was for 1.85M shares at the same price range.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs